@article{ATM10411,
author = {Despoina Moumtzi and Sofia Lampaki and Paul Zarogoulidis and Konstantinos Porpodis and Kalliopi Lagoudi and Wolfgang Hohenforst-Schmidt and Athanasia Pataka and Theodora Tsiouda and Athanasios Zissimopoulos and George Lazaridis and Vasilis Karavasilis and Helen Timotheadou and Nikolaos Barbetakis and Pavlos Pavlidis and Theodoros Kontakiotis and Konstantinos Zarogoulidis},
title = {Prognostic factors for long term survival in patients with advanced non-small cell lung cancer},
journal = {Annals of Translational Medicine},
volume = {4},
number = {9},
year = {2016},
keywords = {},
abstract = {Background: Non-small cell lung cancer (NSCLC) represents 85% of all lung cancers. It is estimated that 60% of patients with NSCLC at time of diagnosis have advanced disease. The aim of this study was to investigate clinical and demographic prognostic factors of long term survival in patients with unresectable NSCLC.
Methods: We retrospectively reviewed data of 1,156 patients with NSCLC stage IIIB or IV who survived more than 60 days from the time of diagnosis and treated from August 1987 until March 2013 in the Oncology Department of Pulmonary Clinic of the General Hospital Papanikolaou. Initially univariate analysis using the log-rank test was conducted and then multivariate analysis using the proportional hazards model of Cox. Also Kaplan Meier curves were used to describe the distribution of survival times of patients. The level of significance was set at 0.05.
Results: The mean age at diagnosis was 62 years. About 11.9% of patients were women and 88.1% were male. The majority of cases were adenocarcinomas (42.2%), followed squamous (33%) and finally the large cell (6%). Unlike men, most common histological type among women was adenocarcinoma rather than squamous (63% vs. 10.9%). In univariate analysis statistically significant factors in the progression free survival (PFS) and overall survival (OS) were: weight loss ≥5%, histological type, line 1 drugs, line 1 combination, line 1 cycles and radio lung. Specifically radio lung gives clear survival benefit in the PFS and OS in stage IIIB (P=0.002) and IV (P},
issn = {2305-5847}, url = {https://atm.amegroups.org/article/view/10411}
}